MPW
BCRX icon

MA Private Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

MA Private Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,700
Closed -$76.1K – 69
2023
Q4 		$76.1K Buy
+12,700
New +$73.6K 0.02% 76

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

MA Private Wealth's BCRX Position: Q1 2024 in Review

MA Private Wealth sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 12,700 shares — an estimated $76.1K sold.

MA Private Wealth first reported a position in BCRX in Q4 2023 and held it in 1 quarter. The position peaked at $76.1K in Q4 2023. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • MA Private Wealth reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • MA Private Wealth sold 12,700 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $76.1K.
  • MA Private Wealth first reported a position in BioCryst Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • MA Private Wealth's BioCryst Pharmaceuticals position peaked at $76.1K in Q4 2023.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on MA Private Wealth's 13F filing for Q1 2024, filed 30 Apr 2024.